PICO Portalanswers from OpenAlex & ORCID
Matthew H. Taylor
ResearcherPublications, citations & collaboration network
Matthew H. Taylor is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Matthew H. Taylor have?
PICO Portalindexed works
Matthew H. Taylor has 297 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Matthew H. Taylor have?
PICO Portalcitation count
Matthew H. Taylor has 20,671 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Matthew H. Taylor?
PICO Portalh-index
Matthew H. Taylor has an h-index of 49 in OpenAlex.
What is the i10-index of Matthew H. Taylor?
PICO Portali10-index
Matthew H. Taylor has an i10-index of 119 in OpenAlex.
What is the ORCID of Matthew H. Taylor?
PICO Portalorcid
The ORCID for Matthew H. Taylor is on the source record.
What is the OpenAlex record for Matthew H. Taylor?
PICO Portalopenalex
The OpenAlex for Matthew H. Taylor is on the source record.
What are the most-cited papers on Matthew H. Taylor?
PICO Portalmost cited works
Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children
Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar, Steven G. DuBois, Ulrik Lassen, George D. Demetri, Michael J. Nathenson, Robert C. Doebele, Anna F. Farago, Alberto S. Pappo, Brian Turpin, Afshin Dowlati, Marcia S. Brose, Leo Mascarenhas, Noah Federman, Jordan Berlin, Wafik S. El‐Deiry, Christina S. Baik, John F. Deeken, Valentina Boni, Ramamoorthy Nagasubramanian, Matthew H. Taylor, Erin R. Rudzinski, Funda Meric‐Bernstam, Davendra Sohal, C. Patrick, Luis E. Raez, Jaclyn F. Hechtman, Ryma Benayed, Marc Ladanyi, Brian B. Tuch, Kevin Ebata, Scott Cruickshank, Nora Ku, Michael C. Cox, Douglas S. Hawkins, David S. Hong, David M. Hyman
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger, Makoto Tahara, Lori J. Wirth, Bruce Robinson, Marcia S. Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H. Shah, Ana O. Hoff, Andrew G. Gianoukakis, Naomi Kiyota, Matthew H. Taylor, Sung‐Bae Kim, Monika K. Krzyzanowska, Corina E. Dutcus, Begoña de las Heras, Junming Zhu, Steven I. Sherman
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
Lori J. Wirth, Eric J. Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen H. Lorch, Francis P. Worden, Marcia S. Brose, Jyoti D. Patel, Sophie Leboulleux, Yann Godbert, Fabrice Barlési, John C. Morris, Taofeek K. Owonikoko, Daniel S.W. Tan, Oliver Gautschi, Jared Weiss, Christelle de la Fouchardière, Mark E. Burkard, Janessa Laskin, Matthew H. Taylor, Matthias Kroiß, Jacques Médioni, Jonathan W. Goldman, Todd M. Bauer, Benjamin Levy, Viola W. Zhu, Nehal J. Lakhani, Víctor Moreno, Kevin Ebata, Michele Nguyen, Dana Heirich, Edward Y. Zhu, Xin Huang, Luxi Yang, Jennifer Kherani, S. Michael Rothenberg, Alexander Drilon, Vivek Subbiah, Manisha H. Shah, Maria E. Cabanillas
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Vicky Makker, Matthew H. Taylor, Carol Aghajanian, Ana Oaknin, James W. Mier, Allen Lee Cohn, Margarita Romeo, Raquel Bratos, Marcia S. Brose, Christopher DiSimone, Mark Messing, Daniel E. Stepan, Corina E. Dutcus, Jane Wu, Emmett V. Schmidt, Robert Orlowski, Pallavi Sachdev, Robert Shumaker, Antonio Casado
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
Justin F. Gainor, Giuseppe Curigliano, Dong‐Wan Kim, Ki Hyeong Lee, Benjamin Besse, Christina S. Baik, Robert C. Doebele, Philippe A. Cassier, Gilberto Lopes, Daniel S.W. Tan, Elena Garralda, Luis Paz‐Ares, Byoung Chul Cho, Shirish M. Gadgeel, Michael Thomas, Stephen V. Liu, Matthew H. Taylor, Aaron S. Mansfield, Viola W. Zhu, Corinne Clifford, Hui Zhang, Michael Palmer, Jennifer Green, Christopher D. Turner, Vivek Subbiah